NDAORALTABLET
Approved
Dec 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
DARVOCET-N 50 (acetaminophen; propoxyphene napsylate) by Teva. Approved for minor aches, pains due to: headache sore throat flu toothache the common cold temporarily reduces fever. First approved in 1972.
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DARVOCET-N 50 is an oral tablet combining acetaminophen with propoxyphene napsylate, indicated for minor aches and pains including headache, sore throat, flu, toothache, and common cold symptoms with fever reduction. The mechanism of action involves central analgesic and antipyretic effects, though precise pathways are not fully established. This is a mature, generic-exposed combination analgesic with declining clinical relevance in modern pain management.
LOE Approaching
As a product approaching loss of exclusivity with moderate competitive pressure (30%), career opportunities are concentrated in supply chain optimization and generic transition planning rather than growth-focused commercial roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on DARVOCET-N 50 at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.